Abstract
Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Current Pharmaceutical Design
Title: Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Volume: 18 Issue: 6
Author(s): Burak Pamukcu, Kurt Huber and Gregory Y.H. Lip
Affiliation:
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Abstract: Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Export Options
About this article
Cite this article as:
Pamukcu Burak, Huber Kurt and Y.H. Lip Gregory, Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277716
DOI https://dx.doi.org/10.2174/138161212799277716 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Effects of Ambient Pollutant Particles and Metals
Current Vascular Pharmacology Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Advances in Antithrombotic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Serotonin Reuptake Inhibitors and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Optimal Dosing Design for Antibiotic Therapy in the Elderly: A Pharmacokinetic and Pharmacodynamic Perspective
Recent Patents on Anti-Infective Drug Discovery NO Signaling Through cGMP in Renal Tissue Fibrosis and Beyond: Key Pathway and Novel Therapeutic Target
Current Medicinal Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology Is There any Correlation Between Diabetic Retinopathy and Risk of Cardiovascular Disease?
Current Diabetes Reviews Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing
Current Pharmacogenomics and Personalized Medicine Importance of Assessing the Effect of Statins on the Function of High- Density Lipoproteins on Coronary Plaque
Cardiovascular & Hematological Disorders-Drug Targets Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Current Vascular Pharmacology